Compare NiSource Inc Common Stock (NI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

NiSource (NI) trades at $41.49, up 0.63% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28, 2026. Fundamentals show solid profitability with a 13.15% net income margin and a P/E of 22.07. Recent news highlights dividend declarations and institutional buying interest, though the stock faces headwinds from storm recovery costs and interest rate sensitivity.

The outlook remains positive given analyst consensus with a $49.57 price target and 73% buy ratings. Key opportunities include data center demand growth and regulatory support, while risks involve volatile cash flows, high debt levels, and potential earnings pressure from operational disruptions. Investors should weigh the stable dividend yield against execution risks in a rising rate environment.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.